帕利哌酮与利培酮治疗精神分裂症的疗效和安全性Meta分析

Comparison of Efficacy and Safety of Paliperidone and Risperidone in Treatment of Schizophrenia by Meta Analysis

关键词:  精神分裂症  帕利哌酮  利培酮  疗效  安全性  Meta分析

Key words:  schizophrenia  paliperidone  risperidone  efficacy  safety  Meta analysis

摘要:

目的 评价帕利哌酮与利培酮治疗精神分裂症疗效和安全性的差异。方法 应用循证医学方法对符合标准的16项研究进行分析，评价帕利哌酮与利培酮治疗精神分裂症过程中有效率、治疗后量表评分及不良反应等的差异。结果 帕利哌酮与利培酮治疗精神分裂症的有效率和治疗后量表评分的差异均有统计学意义；两者治愈率差异无统计学意义；帕利哌酮组锥体外系反应、失眠、泌乳及月经紊乱、肝功能异常的发生率明显低于利培酮组，两者具有显著性统计学差异。结论 帕利哌酮疗效优于利培酮，不良反应的发生率明显低于利培酮。

Abstract:

OBJECTIVE To compare the efficacy and safety of paliperidone and risperidone in treatment of schizophrenia. METHODS Standard 16 studies were analyzed by evidence-based medicine, differences in efficiency, cure rate, scale score and adverse reactions of paliperidone and risperidone in the treatment of schizophrenia were evaluated. RESULTS There were significant differences in efficiency and scale score of paliperidone and risperidone in the treatment of schizophrenia. The incidence of extrapyramidal reactions, insomnia, lactation and menstrual disorders, abnormal liver function in paliperidone group was significantly lower than risperidone group. CONCLUSION Paliperidone is more effective than risperidone, and has lower incidence of adverse reactions.